Alnylam Pharmaceuticals Inc

ALNY

328.160USD

-3.080-0.93%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Alnylam Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

38 / 159

Overall Ranking

109 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Alnylam Pharmaceuticals Inc Highlights

StrengthsRisks

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 116.72% year-on-year.

Overvalued

The company’s latest PE is 1010.56, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 132.38M shares, decreasing 0.01% quarter-over-quarter.

Held by ETHSX

Star Investor ETHSX holds 7.70K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.39.

Analyst Rating

Based on 30 analysts

Buy

Current Rating

473.082

Target Price

+34.41%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Alnylam Pharmaceuticals Inc is 8.70, ranking 44 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 1.25B, representing a year-over-year increase of 149.35%, while its net profit experienced a year-over-year increase of 325.05%.

Score

Industry at a Glance

Previous score

8.70

Change

0



Financials

7.27

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.59

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.66

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Alnylam Pharmaceuticals Inc is 7.42, ranking 71 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 1010.56, which is 44.23% below the recent high of 1457.49 and 150.63% above the recent low of -511.69.

Score

Industry at a Glance

Previous score

7.42

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 38/159

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Alnylam Pharmaceuticals Inc is 7.87, ranking 94 out of 159 in the Pharmaceuticals industry. The average price target is 500.00, with a high of 580.00 and a low of 236.00.

Score

Industry at a Glance

Previous score

7.87

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Alnylam Pharmaceuticals Inc is 6.66, ranking 115 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 382.99 and the support level at 299.92, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.73

Change

-0.07

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Alnylam Pharmaceuticals Inc is 10.00, ranking 1 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 102.07%, representing a quarter-over-quarter decrease of 0.31%. The largest institutional shareholder is The Vanguard, holding a total of 13.49M shares, representing 10.21% of shares outstanding, with 2.43% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Capital World Investors

16.43M

-2.21%

Fidelity Management & Research Company LLC

15.91M

+5.68%

The Vanguard Group, Inc.

Star Investors

13.51M

+2.02%

Capital Research Global Investors

7.22M

+0.43%

BlackRock Institutional Trust Company, N.A.

6.59M

+0.81%

JP Morgan Asset Management

3.87M

+115.83%

State Street Investment Management (US)

3.08M

-2.89%

Baillie Gifford & Co.

Star Investors

2.79M

-8.00%

Geode Capital Management, L.L.C.

2.50M

+4.19%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Alnylam Pharmaceuticals Inc is 6.33, ranking 56 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.36. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Alnylam Pharmaceuticals Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Alnylam Pharmaceuticals Inc

ALNY

7.83 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mckesson Corp

MCK

9.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Gilead Sciences Inc

GILD

8.92 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

8.86 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Regeneron Pharmaceuticals Inc

REGN

8.72 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mirum Pharmaceuticals Inc

MIRM

8.70 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment